Drug compounding supplier Arseus buys U.S.-based Freedom Pharma
BRUSSELS (Reuters) - Belgium-based Arseus (RCUS.BR), the world's biggest supplier of ingredients to pharmacists so they can mix up their own versions of drugs, bought U.S.-based Freedom Pharmaceuticals for an undisclosed sum, it said on Thursday.
The acquisition strengthens its global position in the market for drug compounding, where pharmacists assemble medicines themselves specifically tailored to the needs of their customers.
Arseus said in a statement that it paid 5.5 times EBITDA for Freedom Pharmaceuticals, which expects to achieve turnover of about $25 million in 2013.
(Reporting By Ben Deighton, Editing By Ethan Bilby)
WASHINGTON - Start-up companies will be able to raise much more capital through certain public stock deals without facing costly regulatory burdens under a proposal announced by U.S. securities regulators on Wednesday.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.